<bill session="116" type="h" number="8529" updated="2020-12-10T08:15:44Z">
  <state datetime="2020-10-06">REFERRED</state>
  <status>
    <introduced datetime="2020-10-06"/>
  </status>
  <introduced datetime="2020-10-06"/>
  <titles>
    <title type="display">Protecting Access to Affordable Medicines Act of 2020</title>
    <title type="short" as="introduced">Protecting Access to Affordable Medicines Act of 2020</title>
    <title type="official" as="introduced">To amend title XIX of the Social Security Act to prohibit additional rebates under the Medicaid program for certain noninnovator multiple source drugs.</title>
  </titles>
  <sponsor bioguide_id="B001251"/>
  <cosponsors>
    <cosponsor bioguide_id="B001311" joined="2020-12-09"/>
    <cosponsor bioguide_id="C001097" joined="2020-10-06"/>
    <cosponsor bioguide_id="L000576" joined="2020-10-06"/>
    <cosponsor bioguide_id="M001180" joined="2020-10-30"/>
    <cosponsor bioguide_id="O000171" joined="2020-10-20"/>
    <cosponsor bioguide_id="S001200" joined="2020-10-27"/>
  </cosponsors>
  <actions>
    <action datetime="2020-10-06">
      <text>Introduced in House</text>
    </action>
    <action datetime="2020-10-06" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
  </actions>
  <committees>
    <committee subcommittee="" code="HSIF" name="House Energy and Commerce" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Home and outpatient care"/>
    <term name="Inflation and prices"/>
    <term name="Medicaid"/>
    <term name="Prescription drugs"/>
    <term name="State and local government operations"/>
  </subjects>
  <amendments/>
  <summary date="2020-10-06T04:00:00Z" status="Introduced in House">Protecting Access to Affordable Medicines Act of 2020

This bill prohibits additional rebates for certain drugs under the Medicaid Drug Rebate Program. Specifically, the bill prohibits additional rebates with respect to noninnovator multiple-source drugs (i.e., generics) for which the average manufacturer price is less than $1.</summary>
  <committee-reports/>
</bill>
